IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer

Due to lack of targetable receptors and intertumoral heterogeneity, triple negative breast cancer (TNBC) remains particularly difficult to treat. Doxorubicin (DOX) is typically used as nonselective neoadjuvant chemotherapy, but the diversity of treatment efficacy remains unclear. Comparable to varia...

Descripción completa

Detalles Bibliográficos
Autores principales: Hum, Nicholas R., Sebastian, Aimy, Martin, Kelly A., Rios-Arce, Naiomy D., Gilmore, Sean F., Gravano, David M., Wheeler, Elizabeth K., Coleman, Matthew A., Loots, Gabriela G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340269/
https://www.ncbi.nlm.nih.gov/pubmed/35924165
http://dx.doi.org/10.3389/fonc.2022.928474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340269/
https://www.ncbi.nlm.nih.gov/pubmed/35924165
http://dx.doi.org/10.3389/fonc.2022.928474

Ejemplares similares